Skip to main content
Premium Trial:

Request an Annual Quote

GeneProt Slashes Staff in Half; Will Refocus Customer Base

NEW YORK, April 3 - Swiss proteomics company GeneProt will lay off 45 of its 95 staff as part of a broad reorganization it said is largely the result of a deteriorating business climate.

 

CEO Bertrand Damour told GenomeWeb the company will lay off the staffers in two weeks in accordance with a Swiss employment law. He also stressed that the company, which discovers and manufactures proteins it hopes might be used to treat certain common diseases, is now equipped technologically to where it can operate with the reduced headcount.

"The big pharmaceutical companies are also facing a financial crisis, and they are taking fewer risks with early-stage projects and prefer to invest in internal research projects or in later-stage projects," he said. "We believe our smaller size will allow to perform better in this market. We will now be able to secure deals with more smaller companies rather than hunting for the few big elephants in the market."

 

The news was first reported by Reuters.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.